NCT03975283View on ClinicalTrials.gov

Use of Exparel for Postoperative Analgesia Following Bariatric Surgery

PHASE4UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Post Operative Pain
Interventions
DRUG

Exparel 266 MG Per 20 ML Injection

266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.

DRUG

Bupivacaine Hcl 0.25% Inj

0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

McMaster University

OTHER

NCT03975283 - Use of Exparel for Postoperative Analgesia Following Bariatric Surgery | Biotech Hunter | Biotech Hunter